The move comes after the trial data, when Java is offered limited protection against mild and moderate disease caused by the 501Y.V2 coronavirus virus.
South Africa has suspended the use of the Oxford / AstraZeneca coronavirus vaccine in its vaccination program until a committee of scientists advises on the best way forward.
The announcement came after Health Minister Zweli Makhiz announced Sunday that the test data showed the vaccine developed by drugmaker AstraZeneca and the University of Oxford offered limited protection against only mild and moderate disease, a 501Y.V2 Koronova variant Was first identified in South Africa.
After receiving 1 million doses produced on Monday by the Serum Institute of India, the government soon intended to roll out the Oxford / AstraZeneca shot for health workers.
Instead, it will offer vaccines developed by Johnson & Johnson (J&J) and Pfizer in the coming weeks, while experts consider how the AstraZeneca shot can be deployed.
“When new information is brought to light and viruses change and changes occur, decisions need to be made. This is probably the reason why the AstraZeneca vaccine rollout is on hold so far. In the next few weeks, South Africa will have the J&J and Pfizer vaccine, “The Independent Online Website Was quoted Say hello
The University of Witwatersand in Johannesburg, which tested the Oxford / AstraZeneca vaccine, said in a statement on Sunday that the vaccine “provides minimal protection against mild-to-moderate COVID-19 infection, which is effective in South Africa.”
But in a full letter due to be published on Monday, AstraZeneca said none of the 31 participants had serious symptoms. This may mean that it will still have an impact on critical illness, although there is not enough data to make a definitive decision yet.
The data, which have not yet undergone peer review, “appear to confirm theoretical observations that mutations in the virus in South Africa will allow ongoing transmission of the virus in the vaccinated population”, he said.
“Avoidance of moderate-severe illness, hospitalization, or death could not be assessed in this study because the target population was at low risk.”
A spokesperson for AstraZeneca also said that the company has begun to vaccinate against the variant and “will move rapidly through clinical development so that it is ready for autumn.”